Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%

Intelligent Bio Solutions

13/05/2026 13:47

Overview

U.S. medical technology firm's fiscal Q3 revenue rose 46% yr/yr, driven by cartridge sales

Gross profit margin improved to 50.5% from 46.8% a year ago

Company reported Q3 net loss per share of $1.80

Outlook

Company says it is progressing toward entry into the U.S. drug screening market

Intelligent Bio Solutions expects continued growth through the remainder of fiscal 2026

Company sees expanding gross margins and recurring revenue as key drivers going forward

Result Drivers

CARTRIDGE SALES GROWTH - Q3 cartridge revenue rose 59% yr/yr and accounted for 66% of sales, reflecting recurring demand from the installed base

GROSS MARGIN EXPANSION - Gross profit margin improved to 50.5% in Q3, driven by operational efficiencies, higher sales volumes, and new manufacturing partnership

OTHER SALES INCREASE - Q3 'other' sales rose 80% yr/yr, signaling a broadening product ecosystem and revenue diversification

Company press release: ID:nGNX2jp4gQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Basic EPS
-$1.80


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)